Visit Diabetes News from dLife.com

ONGLYZA (Saxagliptin) Demonstrated Significant Improvements Across Key Measures Of Glucose Control When Added To A Sulfonylurea Or Thiazolidinedione In People With Inadequately Controlled Type 2 Diabetes

Posted on September 08, 2008

September 8, 2008 (Press Release) - Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] when added to a s...

Original article link


back pain , cough , diabetes , diarrhea , hypertension , influenza , joint pain , type 2 diabetes , urinary tract